MiNK Therapeutics (NASDAQ:INKT – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.12), Zacks reports.
MiNK Therapeutics Stock Performance
Shares of MiNK Therapeutics stock opened at $8.52 on Tuesday. The stock has a market capitalization of $33.76 million, a PE ratio of -2.18 and a beta of 0.16. MiNK Therapeutics has a 52 week low of $4.56 and a 52 week high of $19.00. The stock has a 50 day moving average price of $8.93 and a two-hundred day moving average price of $7.74.
Analyst Upgrades and Downgrades
Separately, HC Wainwright lifted their price target on shares of MiNK Therapeutics from $9.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th.
MiNK Therapeutics Company Profile
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
Featured Stories
- Five stocks we like better than MiNK Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Kohl’s Posts Another Kitchen Sink Quarter, But New CEO Has a Plan
- Are Penny Stocks a Good Fit for Your Portfolio?
- Southwest Airlines Could Triple From Here—Here’s How
- How to invest in marijuana stocks in 7 steps
- Salesforce: An Early AI Opportunity With Long-Term Potential
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
